Linthicum, Mark T.
dosReis, Susan
Slejko, Julia F.
Mattingly, T. Joseph II
Bright, Jennifer L. http://orcid.org/0000-0001-7442-3979
Article History
First Online: 28 August 2020
Declarations
:
: No funding was received for the preparation of this commentary.
: Mark T. Linthicum and Jennifer L. Bright hold the positions of Director of Scientific Communications and Executive Director, respectively, at the Innovation and Value Initiative (IVI), a 501(c)(3) non-profit research organization whose members include pharmaceutical companies, patient advocacy organizations, and health systems. Mark. T. Linthicum was previously employed by Precision Health Economics, a health economics consultancy with clients in the life science and insurance industries. Jennifer L. Bright is also President, Momentum Health Strategies. Susan dosReis has received grant funding from the National Institute of Mental Health, the Patient Centered Outcomes Research Institute, the US Food and Drug Administration, Pharmaceutical Research and Manufacturers of America Foundation (PhRMA), and GlaxoSmithKline. Julia F. Slejko reports grants from PhRMA, PhRMA Foundation, Novartis Pharmaceuticals, and Takeda Pharmaceuticals and teaching honorarium from Pfizer, all outside the submitted work. T. Joseph Mattingly II has received research support unrelated to this work from Bristol Myers Squibb and PhRMA as well as consulting fees from G&W Laboratories and the National Health Council, also unrelated to this work.
: Not applicable.
: Not applicable.
: All authors contributed to the planning, drafting, revision, and approval of this commentary.